<DOC>
	<DOCNO>NCT00235911</DOCNO>
	<brief_summary>The primary objective compare effect Symbicort SiT treatment accord NHG-guidelines bronchial hyperresponsiveness asthmatic patient , measure PD20 histamine , validate Bronchial Hyperresponsiveness Questionnaire ( BHQ ) .</brief_summary>
	<brief_title>Symbicort Single Inhaler Therapy Asthma General Practice Setting</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>diagnosis mild moderate asthma , FEV1 ³ 60 % predict normal value prebronchodilator , daily use inhale GCS last 3 month Regular need &gt; 4 inhalation shortacting b2agonist/day , know suspected hypersensitivity investigational drug inhale lactose , use bblocking agent , smoke ³10 packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>